Impact of glucagon-like peptide-1 receptor agonists with guideline-directed medical therapy in patients with heart failure with reduced ejection fraction and type 2 diabetes

This publication has 31 references indexed in Scilit:

• Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes
  Scientific Reports, 2025
• Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
  The Lancet, 2024
• Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure
  JAMA Network Open, 2024
• Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction
  JACC, 2023
• Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
  JAMA, 2022
• Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
  The Lancet, 2019
• Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea
  JAMA, 2019
• Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and Without Diabetes (LIVE)—a Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial
  European Journal of Heart Failure, 2016
• Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction
  JAMA, 2016
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
  New England Journal of Medicine, 2016